Guardant Health reported preliminary Q4 revenue of about $280 million, a 39% year‑over‑year increase that beat estimates, driven by higher volumes in both oncology and screening tests. The company expects roughly 79,000 oncology tests (up 38%) and about 38,000 Shield screening tests — a near 500% increase from Q4 2024. Guardant projects full‑year 2025 revenue near $981 million and reported an anticipated cash and securities position of about $1.3 billion as of Dec. 31, 2025.